- Home
- TSAT vs AVIR Comparison
TSAT vs AVIR Comparison
Compare TSAT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSAT | AVIR |
|---|---|---|
| Founded | 1969 | 2012 |
| Country | Canada | United States |
| Employees | 610 | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.1M | 318.0M |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TSAT | AVIR |
|---|---|---|
| Price | $26.03 | $4.31 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 230.4K | ★ 590.6K |
| Earning Date | 03-26-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $324,440,552.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.77 | $2.46 |
| 52 Week High | $36.85 | $4.50 |
Technical Indicators
Market Signals| Indicator | TSAT | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 64.42 |
| Support Level | $25.28 | $4.04 |
| Resistance Level | $28.95 | $4.50 |
| Average True Range (ATR) | 2.26 | 0.24 |
| MACD | -0.18 | 0.02 |
| Stochastic Oscillator | 40.98 | 80.67 |
Price Performance
Historical ComparisonAbout TSAT Telesat Corporation
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).